SC
TAK icon

Schubert & Co’s Takeda Pharmaceutical TAK Stock Holding History

Schubert & Co’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-389
Closed -$6.41K – 1341
2023
Q1 		$6.41K Sell
389
-30
-7% -$478 0.01% 357
2022
Q4 		$6.54K Sell
419
-262
-38% -$3.66K 0.01% 333
2022
Q3 		$9K Buy
681
+109
+19% +$1.52K 0.01% 221
2022
Q2 		$8K Buy
+572
New +$8.16K 0.01% 215

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Schubert & Co's TAK Position: Q2 2023 in Review

Schubert & Co sold out of Takeda Pharmaceutical (TAK) in Q2 2023, closing a stake of 389 shares — an estimated $6.41K sold.

Schubert & Co first reported a position in TAK in Q2 2022 and held it in 4 quarters. The position peaked at $9K in Q3 2022. 310 funds tracked by Wall St. Rank hold TAK as of Q2 2023.

  • Schubert & Co reported no remaining Takeda Pharmaceutical position as of Q2 2023 after selling out during the quarter.
  • Schubert & Co sold 389 Takeda Pharmaceutical shares in Q2 2023, an estimated $6.41K.
  • Schubert & Co first reported a position in Takeda Pharmaceutical in Q2 2022 and held it in 4 quarters.
  • Schubert & Co's Takeda Pharmaceutical position peaked at $9K in Q3 2022.
  • 310 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.